logo

Learning the interaction rules of antibody-antigen binding

Sector: Commercial • Location: Norway

Source: EU Funding & Tenders Portal

Project
Ongoing

Antibody-antigen binding is the basis of two fundamental biotherapeutic pillars: monoclonal antibodies (1) and vaccines (2). To accelerate therapeutics discovery, we need to perform antibody (Ab) and antigen (Ag) design in silico. Specifically, we need to address a fundamental immuno-biotechnological challenge: understanding the interaction rules that predict Ab-Ag binding. Solving this challenge

Status
Under Construction
Sector
Commercial, Government
Location
Norway
Updated
22 Jul 2026
Source
EU Funding & Tenders Portal

ConstructChat

Ask ConstructChat about Learning the interaction rules of antibody-antigen binding

Pick a question to edit it, or write your own.

First answer free · no account

I am a

Project Information FAQ

Project Information

4 Q
The project “Learning the interaction rules of antibody-antigen binding” is an infrastructure initiative in the Commercial sector, located in Norway. Taiyo aggregates data on it from EU Funding & Tenders Portal.

Participants

Sponsoring Agency

Status

Original status

ongoing

Taiyo status

Under Construction

Taiyo last update

2026-07-22

Contact

Not available for this record.

Description

Description

Antibody-antigen binding is the basis of two fundamental biotherapeutic pillars: monoclonal antibodies (1) and vaccines (2). To accelerate therapeutics discovery, we need to perform antibody (Ab) and antigen (Ag) design in silico. Specifically, we need to address a fundamental immuno-biotechnological challenge: understanding the interaction rules that predict Ab-Ag binding. Solving this challenge demands the convergence of biotechnology, computational structural biology, and machine learning (ML). My lab is one of the few worldwide to have this transdisciplinary expertise. Research problem: Currently, the predictive performance of Ab-Ag binding is poor, and an understanding of the underlying rules of Ab-Ag binding is mostly absent. We previously showed that both unprecedentedly large datasets (>10^5 Ab-Ag sequence pairs) and extensive structural information on the Ab-Ag binding interface (paratope, epitope) are needed to increase prediction accuracy and recover binding rules. Targeted breakthrough: To address the lack of large-scale Ab-Ag sequence and structural data, we will develop a method for high-throughput screening of >10^3 Ab paratope-mutated variants binding to >10^3 of Ag epitope-mutated variants, generating sequence data of Ab-Ag binding pairs at an unprecedented scale (>10^6 sequence Ab-Ag pairs). Structural information of the entirety of the sequence-based Ab-Ag binding data will be generated by building and innovating on recent breakthroughs in computational structural biology. To derive Ab-Ag interaction rules from the generated data, we will develop ML techniques for Ab-Ag binding prediction and rule recovery. We will demonstrate experimentally that we have begun to understand Ab-Ag interaction rules. Impact: The proposed research generates the exact data necessary to recover the rules of Ab-Ag binding and provides a first groundbreaking insight into those rules, moving us closer to in silico on-demand antibody and vaccine design.

Location

Country

Norway

Source

Source

EU Funding & Tenders Portal

URL

More Details

Record type

Project

Sector

Commercial, Government

Article published date

2026-03-01

More on this project

Research

Free account

View all details

You are reading the public part. A free account opens the rest:

  • Every detail on this project
  • News and media coverage
  • Technical research
View all details

Free account · no card · lands you back on this project